Related Experiment Video

Updated: Apr 12, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

5.6K

Present and future of personalized medicine in adult genitourinary tumors

Chiara Ciccarese1, Matteo Santoni, Francesco Massari

  • 1Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy.

Future Oncology (London, England)
|May 9, 2015
PubMed

Insights

Targeted therapies have transformed genitourinary cancer treatment, but patient selection remains empirical. Genomic insights are paving the way for personalized medicine in prostate, renal, and bladder cancers.

Area of Science:

  • Oncology
  • Genitourinary Cancer Research
  • Personalized Medicine

Background:

  • Targeted agents have revolutionized genitourinary tumor treatment.
  • Validated biomarkers for tumor response or patient tolerability are lacking.
  • Current patient selection for targeted therapies is empirical.

Purpose of the Study:

  • To review recent findings and emerging individualized therapies for genitourinary tumors.
  • To focus on prostate, renal, and bladder cancer.
  • To discuss the promises and limitations of personalized approaches.

Main Methods:

  • Literature review of recent advancements in genomic sequencing and molecular characterization.
  • Analysis of personalized strategies based on genomic and molecular profiles.
  • Overview of targeted agents and individualized therapies.

Main Results:

  • Genomic sequencing and molecular characterization have identified complex genomic abnormalities.
  • Knowledge of cancer biological landscapes has increased significantly.
  • Personalized strategies are being developed based on patient and tumor profiles.

Conclusions:

  • Personalized medicine holds promise for genitourinary cancers.
  • Further research is needed to overcome limitations in biomarker validation and patient selection.
  • Individualized therapies based on genomic profiles are emerging for prostate, renal, and bladder cancers.
Keywords:
bladder cancergenitourinary tumorspersonalized therapyprostate cancerrenal cell carcinomatargeted therapy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
92
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K